Catastrophic antiphospholipid (Asherson's) syndrome and genetic thrombophilic disorders in obstetrics

被引:14
作者
Makatsariya, A.
Asherson, R. A.
Bitsadze, V.
Baimuradova, S.
Akinshina, S.
机构
[1] Moscow Med Acad, Dept Obstet & Gynecol, Moscow 119017, Russia
[2] Univ Witwatersrand, Sch Pathol, Div Immunol, Johannesburg, South Africa
关键词
catastrophic antiphospholipid; syndrome (Asherson's syndrome); thrombophilia; obstetric complications; inflammation; endothelial dysfunction;
D O I
10.1016/j.autrev.2006.06.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Catastrophic antiphospholipid syndrome (CAPS) (Asherson's Syndrome), is a life-threatening condition characterized by a rapidly progressive thromboses resulting in a multiorgan dysfunction syndrome (MODS), evidence of systemic inflammatory response syndrome (SIRS) in the presence of antiphospholipid antibodies. CAPS differs from the classic APS by predominantly affecting small vessels, involvement of unusual organs, rapid onset of MODS, and the development of acute respiratory distress syndrome (ARDS) in 25% of patients, which is a feature of SIRS. Obstetric-related multiorgan failure may be a feature of a subset of CAPS more frequently than was previously thought. Patients with obstetric complications should be tested for antiphospholipid antibodies and genetic thrombophilia in order to institute early prophylaxis. Low-molecular-weight heparin is the drug of choice for preventing obstetric complications and CAPS due to its anticoagulant and anti-inflammatory properties. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 26 条
[1]   Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome [J].
Asherson, RA .
IMMUNOBIOLOGY, 2005, 210 (10) :727-733
[2]   Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome:: clinical and haematological characteristics of 23 patients [J].
Asherson, RA ;
Espinosa, G ;
Cervera, R ;
Gómez-Puerta, JA ;
Musuruana, J ;
Bucciarelli, S ;
Ramos-Casal, M ;
Martínez-González, AL ;
Ingelmo, M ;
Reverter, JC ;
Font, J ;
Triplett, DA .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :943-946
[3]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[4]  
ASHERSON RA, 1992, J RHEUMATOL, V19, P508
[5]  
Asherson RA, 2000, J RHEUMATOL, V27, P12
[6]   Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study [J].
Brenner, B ;
Hoffman, R ;
Carp, H ;
Dulitsky, M ;
Younis, J .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) :227-229
[7]  
BUCCIARELLI S, IN PRESS CAPS ARTHRI
[8]   Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications [J].
Carmona, F ;
Lázaro, I ;
Reverter, JC ;
Tàssies, D ;
Font, J ;
Cervera, R ;
Balasch, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 194 (02) :457-465
[9]   Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics [J].
Cervera, R ;
Asherson, RA .
IMMUNOBIOLOGY, 2005, 210 (10) :735-741
[10]   Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome [J].
Cervera, R ;
Font, J ;
Gómez-Puerta, JA ;
Espinosa, G ;
Cucho, M ;
Bucciarelli, S ;
Ramos-Casals, M ;
Ingelmo, M ;
Piette, JC ;
Shoenfeld, Y ;
Asherson, RA .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1205-1209